Evropenem (meropenem) powder for solution for injections 1g. №10 vial

Description

Evropenem Composition
active substance: meropenem;

1 bottle contains meropenem (as meropenem trihydrate) 500 mg;

1 bottle contains meropenem (as meropenem trihydrate) 1000 mg;

excipient: sodium carbonate.

Evropenem Dosage form.

Powder for solution for injection.

Basic physical and chemical properties: powder from white to slightly yellowish.

Pharmacotherapeutic group. Antimicrobial agents for systemic use. Carbapenems. ATX code J01D H02.

Evropenem  Pharmacological properties

Pharmacodynamics.

Meropenem has a bactericidal effect by inhibiting the synthesis of bacterial cell walls of gram-positive and gram-negative bacteria by binding to penicillin binding proteins (PBPs).

As with other beta-lactam antibacterial agents, the times at which the concentration of meropenem exceeded the minimum inhibitory concentration (MIS) indicated a high degree of correlation with efficacy. In preclinical models, meropenem demonstrated activity at plasma concentrations exceeding the MIS for infectious microorganisms by about 40% in the dosing interval.

Bacterial resistance to meropenem can result from:

a decrease in the permeability of the outer membrane of gram-negative bacteria (due to a decrease in the production of porins);
decreasing affinity with target PBPs;
increasing the expression of eflux pump components;
production of beta-lactamases, which can hydrolyze carbapenems.
Cases of infectious diseases caused by bacteria resistant to carbapenems have been reported.

There is no cross-resistance between meropenem and drugs belonging to the classes of quinolones, aminoglycosides, macrolides and tetracyclines, taking into account the target microorganisms. However, bacteria can show resistance to more than one class of antibacterial drugs when the mechanism involved includes impermeability of the cell membrane and / or the presence of efflux pump (s).

Indications
Meropenem is indicated for the treatment of such infections in adults and children from 3 months of age:

severe pneumonia, including community-acquired and hospital-acquired pneumonia;
bronchopulmonary infections with cystic fibrosis;
complicated urinary tract infections;
complicated intra-abdominal infections;
infections during childbirth and postpartum infections;
complicated infections of the skin and soft tissues;
acute bacterial meningitis.
Meropenem can be used to treat neutropenic and febrile patients with suspected bacterial infection.

Consideration should be given to providing a formal recommendation for the appropriate use of antibacterial drugs.

Contraindications
Hypersensitivity to the active substance or excipient of the drug.

Hypersensitivity to any other antibacterial agent of the carbapenem group.

Severe hypersensitivity (eg, anaphylactic reactions, severe skin reactions) to any other type of beta-lactam antibacterial agent (eg, penicillins or cephalosporins).